SEC Form 4 · accession 0001213900-18-005618
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua Hexter
Officer — Chief Operating Officer
Period of report
May 3, 2018
Accepted (ET)
May 7, 2018 · 4:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $6.70 | May 3, 2018 | A | 30,000 | A | — | May 3, 2028 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The Stock Option will vest in 16 equal installments of 1,875 on the last day of each quarter commencing June 30, 2018.